The prevalence rate of chronic hepatitis B and C among pulmonary TB patients Source: Annual Congress 2008 - Tuberculosis in immigrants, disadvantaged populations, elderly, HIV-seropositives and in other risk groups Year: 2008
Results of treatment of patients with pulmonary tuberculosis combined with HIV infection and hepatitis Source: International Congress 2018 – Tuberculosis comorbidities Year: 2018
The risk of hepatotoxicity of anti-tuberculosis drugs in patients from regions with high prevalence of hepatitis B Source: Eur Respir J 2001; 18: Suppl. 33, 312s Year: 2001
The impact of bedaquiline and delamanid containing regimens on liver function in patients multi-infected with pulmonary DR-TB, HIV and viral hepatitis Source: International Congress 2019 – Tuberculosis: treatment and management Year: 2019
Risk factors of drug -induced hepatitis among patients with TB/HIV co-infection Source: Annual Congress 2010 - Adverse events of antituberculosis treatment and comorbidities Year: 2010
Prevalence of hepatitis c virus infection among patients with COPD Source: Annual Congress 2009 - COPD: exacerbation and clinical problems Year: 2009
Introduction of a Latent TB infection (LTBI) screening programme detects cases of active tuberculosis and hepatitis B and C Source: International Congress 2018 – Tuberculosis transmission and screening strategies Year: 2018
Bedaquiline in the treatment of patients with co-infection HIV/tuberculosis Source: International Congress 2018 – Drug-resistant tuberculosis and the sequelae of pulmonary tuberculosis Year: 2018
The frequency of respiratory infections in patients with chronic hepatitis C treated with pegylated-Interferon Source: International Congress 2015 – Immunodepression and severe pneumonia Year: 2015
The clinical flow and efficiency of treatment of pulmonary tuberculosis in patients with chorine organic pasticides and viral hepatitis ‘B‘ markers Source: Eur Respir J 2004; 24: Suppl. 48, 50s Year: 2004
The treatment of tuberculosis and application of HAART (highly active anti retroviral treatment) in HIV positive patients Source: Annual Congress 2005 - Challenges in the management of pulmonary tuberculosis: a continuous clinical problem Year: 2005
Prevalence of hepatitis C virus in patients with tuberculosis and its impact in the incidence of anti-tuberculosis drugs induced hepatotoxicity Source: International Congress 2015 – Screening strategies in TB Year: 2015
High prevalence of hepatitis C among patients with drug-resistant tuberculosis and its impact on the treatment outcome in Azerbaijan prisons Source: International Congress 2015 – Screening strategies in TB Year: 2015
Safety of bedaquiline for treatment of MDR/XDR tuberculosis in HIV co-infected patients Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities Year: 2019
Risk of adverse effects of antitubercular drugs in patients with pulmonary tuberculosis and low active viral hepatitis C and other digestive tract diseases Source: Annual Congress 2008 - Tuberculosis in immigrants, disadvantaged populations, elderly, HIV-seropositives and in other risk groups Year: 2008
Features of TB/HIV co-infection and treatment outcome Source: Annual Congress 2012 - Tuberculosis: clinical findings III Year: 2012
A case of acute interstitial pneumonia which developed during the interferon and ribavirin treatment for chronic hepatitis C Source: Eur Respir J 2005; 26: Suppl. 49, 84s Year: 2005
Sarcoidosis associated with interferon-α therapy for chronic hepatitis C Source: Eur Respir J 2006; 28: Suppl. 50, 541s Year: 2006
Influence of viral hepatitis and anti-TB drugs on hepatocyte disfunction in patients with MDR/XDR tuberculosis Source: Virtual Congress 2021 – The ongoing threat of drug-resistant tuberculosis Year: 2021
The incidence of hepatitis C virus in patients with lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 94s Year: 2006